Standard Dosing for Nivolumab
Nivolumab (Opdivo) follows fixed or weight-based dosing schedules approved by the FDA, depending on the cancer type and treatment line. For example:
- Melanoma or NSCLC: 240 mg every 2 weeks or 480 mg every 4 weeks intravenously.
- Renal cell carcinoma: 240 mg every 2 weeks or 480 mg every 4 weeks.
These do not include adjustments based on tumor response, such as reducing dose if the cancer shrinks or stopping early if there's no response.[1]
When Do Doctors Adjust or Stop Nivolumab?
Adjustments occur for toxicity (e.g., immune-related adverse events like pneumonitis), not response. Guidelines from NCCN and FDA recommend:
- Withholding for grade 2 toxicities, resuming at the same dose if resolved.
- Permanent discontinuation for grade 3-4 toxicities or lack of tolerability.
No provisions exist for escalating, de-escalating, or shortening treatment based on response rates or progression-free survival. Treatment continues for 2 years in many adjuvant settings unless toxicity intervenes.[2][3]
What About Response-Based Strategies in Trials?
Ongoing trials explore adaptive dosing, but none are standard. For instance:
- CheckMate studies fixed duration to 2 years based on response durability, not real-time adjustments.
- No approved protocols use biomarkers like PD-L1 expression for dose changes post-initiation; it's used for patient selection.
Physicians monitor response via RECIST criteria every 6-12 weeks, but this guides switching therapies (e.g., to chemo), not nivolumab dose tweaks.[4]
Organ Function or Patient Factors for Adjustments?
Dose adjustments are required for:
- Mild hepatic impairment: No change.
- Moderate: Reduce to 240 mg every 4 weeks or equivalent.
- Renal: No adjustment needed.
Age, body weight (in flat-dose era), or performance status do not trigger changes based on response.[1][5]
[1]: [FDA Opdivo Label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s ws.html)
[2]: NCCN Guidelines: Melanoma (Version 2.2024)
[3]: NCCN Guidelines: NSCLC (Version 5.2024)
[4]: CheckMate-067 Trial (NEJM 2015; updated 2023)
[5]: No specific DrugPatentWatch data on dosing; patents focus on formulation (e.g., US 8,008,449 expires 2028).[6]: DrugPatentWatch: Nivolumab